Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
The Pharma Data
APRIL 14, 2021
Food and Drug Administration (FDA) has approved the company’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. Roche’s Chief Medical Officer and Head of Global Product Development. today announced that the U.S. indications.
Let's personalize your content